Humoral immune response to intralymphatic immunotherapy for disseminated melanoma: Correlation with clinical response

S. S. Ahn, R. F. Irie, T. H. Weisenburger, P. C. Jones, G. Juillard, Denise Roe, D. L. Morton

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Since September 1979, 44 stage III melanoma patients treated with intralymphatic immunotherapy (ILI) with an oncofetal antigen (OFA-I)-enriched tumor cell vaccine (TCV) had evaluable humoral immune responses and clinical follow-up. Fourteen patients (32%) had stabilization or regression of tumors or remained free of resected disease. The median survival was 17 months, compared with 6 months for controls (P < 0.001). Humoral immune responses were monitored by immune adherence using an OFA-positive human melanoma cell line, M14, as target. Alloantibodies were removed by absorption with L14 lymphoblasts autologous to M14. Twenty-two patients (50%) developed elevated antibody titers within 4 months, and 12 of the 22 (55%) had no disease progression. In contrast, 20 of 22 patients (91%) who failed to develop elevated titers had disease progression (P < 0.01). The median titer was significantly higher during the first 4 months in the group whose disease did not progress (P < 0.04). This study demonstrated that ILI with allogeneic OFA-I-enriched TCV can induce objective tumor regression and prolonged survival in patients with disseminated melanoma. Furthermore, because the specific humoral immune response correlates with clinical results, immunization efficacy can be monitored within a short period of time, which should aid future efforts to achieve optimal immunotherapy.

Original languageEnglish (US)
Pages (from-to)362-367
Number of pages6
JournalSurgery
Volume92
Issue number2
StatePublished - 1982
Externally publishedYes

Fingerprint

Humoral Immunity
Immunotherapy
Melanoma
Cancer Vaccines
Disease Progression
Isoantibodies
Survival
Immunization
Neoplasms
Cell Line
Antibodies
oncofetal antigens

ASJC Scopus subject areas

  • Surgery

Cite this

Ahn, S. S., Irie, R. F., Weisenburger, T. H., Jones, P. C., Juillard, G., Roe, D., & Morton, D. L. (1982). Humoral immune response to intralymphatic immunotherapy for disseminated melanoma: Correlation with clinical response. Surgery, 92(2), 362-367.

Humoral immune response to intralymphatic immunotherapy for disseminated melanoma : Correlation with clinical response. / Ahn, S. S.; Irie, R. F.; Weisenburger, T. H.; Jones, P. C.; Juillard, G.; Roe, Denise; Morton, D. L.

In: Surgery, Vol. 92, No. 2, 1982, p. 362-367.

Research output: Contribution to journalArticle

Ahn, SS, Irie, RF, Weisenburger, TH, Jones, PC, Juillard, G, Roe, D & Morton, DL 1982, 'Humoral immune response to intralymphatic immunotherapy for disseminated melanoma: Correlation with clinical response', Surgery, vol. 92, no. 2, pp. 362-367.
Ahn, S. S. ; Irie, R. F. ; Weisenburger, T. H. ; Jones, P. C. ; Juillard, G. ; Roe, Denise ; Morton, D. L. / Humoral immune response to intralymphatic immunotherapy for disseminated melanoma : Correlation with clinical response. In: Surgery. 1982 ; Vol. 92, No. 2. pp. 362-367.
@article{cf6dc6e2ecd34c90b1297377a4c135bf,
title = "Humoral immune response to intralymphatic immunotherapy for disseminated melanoma: Correlation with clinical response",
abstract = "Since September 1979, 44 stage III melanoma patients treated with intralymphatic immunotherapy (ILI) with an oncofetal antigen (OFA-I)-enriched tumor cell vaccine (TCV) had evaluable humoral immune responses and clinical follow-up. Fourteen patients (32{\%}) had stabilization or regression of tumors or remained free of resected disease. The median survival was 17 months, compared with 6 months for controls (P < 0.001). Humoral immune responses were monitored by immune adherence using an OFA-positive human melanoma cell line, M14, as target. Alloantibodies were removed by absorption with L14 lymphoblasts autologous to M14. Twenty-two patients (50{\%}) developed elevated antibody titers within 4 months, and 12 of the 22 (55{\%}) had no disease progression. In contrast, 20 of 22 patients (91{\%}) who failed to develop elevated titers had disease progression (P < 0.01). The median titer was significantly higher during the first 4 months in the group whose disease did not progress (P < 0.04). This study demonstrated that ILI with allogeneic OFA-I-enriched TCV can induce objective tumor regression and prolonged survival in patients with disseminated melanoma. Furthermore, because the specific humoral immune response correlates with clinical results, immunization efficacy can be monitored within a short period of time, which should aid future efforts to achieve optimal immunotherapy.",
author = "Ahn, {S. S.} and Irie, {R. F.} and Weisenburger, {T. H.} and Jones, {P. C.} and G. Juillard and Denise Roe and Morton, {D. L.}",
year = "1982",
language = "English (US)",
volume = "92",
pages = "362--367",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Humoral immune response to intralymphatic immunotherapy for disseminated melanoma

T2 - Correlation with clinical response

AU - Ahn, S. S.

AU - Irie, R. F.

AU - Weisenburger, T. H.

AU - Jones, P. C.

AU - Juillard, G.

AU - Roe, Denise

AU - Morton, D. L.

PY - 1982

Y1 - 1982

N2 - Since September 1979, 44 stage III melanoma patients treated with intralymphatic immunotherapy (ILI) with an oncofetal antigen (OFA-I)-enriched tumor cell vaccine (TCV) had evaluable humoral immune responses and clinical follow-up. Fourteen patients (32%) had stabilization or regression of tumors or remained free of resected disease. The median survival was 17 months, compared with 6 months for controls (P < 0.001). Humoral immune responses were monitored by immune adherence using an OFA-positive human melanoma cell line, M14, as target. Alloantibodies were removed by absorption with L14 lymphoblasts autologous to M14. Twenty-two patients (50%) developed elevated antibody titers within 4 months, and 12 of the 22 (55%) had no disease progression. In contrast, 20 of 22 patients (91%) who failed to develop elevated titers had disease progression (P < 0.01). The median titer was significantly higher during the first 4 months in the group whose disease did not progress (P < 0.04). This study demonstrated that ILI with allogeneic OFA-I-enriched TCV can induce objective tumor regression and prolonged survival in patients with disseminated melanoma. Furthermore, because the specific humoral immune response correlates with clinical results, immunization efficacy can be monitored within a short period of time, which should aid future efforts to achieve optimal immunotherapy.

AB - Since September 1979, 44 stage III melanoma patients treated with intralymphatic immunotherapy (ILI) with an oncofetal antigen (OFA-I)-enriched tumor cell vaccine (TCV) had evaluable humoral immune responses and clinical follow-up. Fourteen patients (32%) had stabilization or regression of tumors or remained free of resected disease. The median survival was 17 months, compared with 6 months for controls (P < 0.001). Humoral immune responses were monitored by immune adherence using an OFA-positive human melanoma cell line, M14, as target. Alloantibodies were removed by absorption with L14 lymphoblasts autologous to M14. Twenty-two patients (50%) developed elevated antibody titers within 4 months, and 12 of the 22 (55%) had no disease progression. In contrast, 20 of 22 patients (91%) who failed to develop elevated titers had disease progression (P < 0.01). The median titer was significantly higher during the first 4 months in the group whose disease did not progress (P < 0.04). This study demonstrated that ILI with allogeneic OFA-I-enriched TCV can induce objective tumor regression and prolonged survival in patients with disseminated melanoma. Furthermore, because the specific humoral immune response correlates with clinical results, immunization efficacy can be monitored within a short period of time, which should aid future efforts to achieve optimal immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0020261872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020261872&partnerID=8YFLogxK

M3 - Article

C2 - 7101129

AN - SCOPUS:0020261872

VL - 92

SP - 362

EP - 367

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 2

ER -